Wuppertal, Germany

Reinhard Sterner



 

Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2019

Loading Chart...
Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Contributions of Reinhard Sterner

Introduction

Reinhard Sterner is a prominent inventor based in Wuppertal, Germany, recognized for his significant contributions to biotechnology. With a patent to his name, his work centers around the development of innovative polypeptides aimed at combating bacterial infections. Sterner's research and inventions reflect a commitment to addressing critical health challenges.

Latest Patents

Reinhard Sterner holds a patent for the "Modified KZ144 endolysin sequence." This invention pertains to polypeptides that exhibit at least about 90% sequence identity with the sequence of SEQ ID NO: 1. These polypeptides are designed to degrade the peptidoglycan of Gram-negative bacteria, enhancing the fight against harmful bacterial strains. Additionally, the patent encompasses nucleic acids encoding such polypeptides, vectors containing these nucleic acids, and corresponding host cells. Further, it includes compositions comprising these innovative elements, showcasing the broad applicability of Sterner's work.

Career Highlights

Reinhard Sterner is associated with Lysando AG, a company focused on biopharmaceutical and biotechnology advancements. His role within the organization underscores his dedication to pioneering solutions for medical and technological challenges. Throughout his career, Sterner has proven to be a valuable asset to his team and the field of biotechnology.

Collaborations

Sterner collaborates with notable colleagues, including Stefan Miller and Heike Stüer. These partnerships reflect a synergistic approach to innovation, combining diverse expertise to tackle complex problems in biotechnology and enhance the effectiveness of their inventions.

Conclusion

Reinhard Sterner exemplifies the spirit of innovation in the ongoing battle against bacterial infections. His patent on the Modified KZ144 endolysin sequence and his collaborations with other professionals in the field contribute to significant advancements in healthcare. His work within Lysando AG positions him at the forefront of biotechnological innovations, inspiring future inventors and researchers to pursue groundbreaking solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…